pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104
Steffen Ormanns(Innsbruck Medical University), Stefan Boeck(German Cancer Research Center)
Cited by 29
Related Papers
Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR
|Cancer Treatment Reviews|2008|205
Pro-Angiogenic Macrophage Phenotype to Promote Myocardial Repair
|Journal of the American College of Cardiology|2019|194
Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer
|British Journal of Cancer|2012|184
Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial
|Journal of Cancer Research and Clinical Oncology|2014|112